Thrivent Financial for Lutherans Purchases 96,274 Shares of DexCom, Inc. (NASDAQ:DXCM)

Thrivent Financial for Lutherans boosted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 44.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 314,102 shares of the medical device company's stock after buying an additional 96,274 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.08% of DexCom worth $21,058,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. AM Squared Ltd bought a new stake in shares of DexCom in the third quarter worth $422,000. Mutual of America Capital Management LLC raised its position in shares of DexCom by 3.8% during the third quarter. Mutual of America Capital Management LLC now owns 57,138 shares of the medical device company's stock worth $3,831,000 after acquiring an additional 2,084 shares during the last quarter. Maxwell Wealth Strategies Inc. lifted its stake in shares of DexCom by 3.3% in the third quarter. Maxwell Wealth Strategies Inc. now owns 10,262 shares of the medical device company's stock worth $708,000 after acquiring an additional 329 shares during the period. Koa Wealth Management LLC increased its position in DexCom by 7.7% during the 3rd quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company's stock valued at $253,000 after purchasing an additional 270 shares during the period. Finally, Empowered Funds LLC raised its holdings in DexCom by 6.1% during the 3rd quarter. Empowered Funds LLC now owns 5,847 shares of the medical device company's stock worth $392,000 after purchasing an additional 335 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Price Performance

Shares of DexCom stock traded down $0.30 on Thursday, reaching $74.94. The stock had a trading volume of 235,046 shares, compared to its average volume of 3,911,010. The business's 50 day moving average is $70.43 and its two-hundred day moving average is $90.34. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a market cap of $29.27 billion, a P/E ratio of 45.05, a price-to-earnings-growth ratio of 2.30 and a beta of 1.17.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on DXCM shares. StockNews.com downgraded DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Royal Bank of Canada decreased their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Robert W. Baird raised their price target on shares of DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, August 5th. Leerink Partners decreased their price objective on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Finally, Morgan Stanley dropped their target price on DexCom from $120.00 to $75.00 and set an "equal weight" rating on the stock in a report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.